Non Hodgkin Lymphoma Clinical Trial

Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin’s Lymphoma

Summary

This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of Waldenstroms Macroglobulinemia
Relapsed or refractory after at least one prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

Any major surgery, chemotherapy or immunotherapy within the last 21 days
Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
Prior autologous stem cell transplant within 6 months of study entry

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

21

Study ID:

NCT03364231

Recruitment Status:

Completed

Sponsor:

TG Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

TG Therapeutics Investigational Trial Site
Washington District of Columbia, 20007, United States
TG Therapeutics Investigational Trial Site
Boston Massachusetts, 02215, United States
TG Therapeutics Investigational Trial Site
Hackensack New Jersey, 07601, United States
TG Therapeutics Investigational Trial Site
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

21

Study ID:

NCT03364231

Recruitment Status:

Completed

Sponsor:


TG Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.